文献速递新发突发、热带与寄生虫病

他非诺喹与伯氨喹预防巴西间日疟复发的实际效果:一项回顾性观察性研究

Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
PubMed 文献 · Lancet Infect Dis · 2024-03-04

该研究在巴西亚马孙地区43家卫生机构评估间日疟根治治疗算法的实际效果。在G6PD正常的16岁及以上患者中,他非诺喹组第90天无复发生效率为88.6%,7天伯氨喹组为83.5%,校正后HR为0.65;第180天两组总体效果相似。

要点

  • 在G6PD正常的16岁及以上患者中,他非诺喹第90天无复发生效率88.6%,7天伯氨喹83.5%。
  • 校正混杂因素后,他非诺喹复发风险约为7天伯氨喹的0.65倍(HR 0.65)。
  • 第180天两组总体效果相似(log-rank p=0.82),他非诺喹中位复发时间92天,伯氨喹68天。

核心结论

  • 在真实世界环境中,G6PD正常的16岁及以上患者中,单剂他非诺喹第90天预防间日疟复发的效果优于7天伯氨喹,而第180天总体效果相似。
  • 作者认为,包含G6PD定量检测和他非诺喹的间日疟根治治疗算法的公共卫生效益支持其在巴西及可能在整个南美洲实施。

研究设计与样本

  • 非干预性观察性研究,使用回顾性数据,在巴西马瑙斯和韦柳港的43家卫生机构实施间日疟治疗算法。
  • 治疗算法包括氯喹(3天共25 mg/kg)和即时定量葡萄糖-6-磷酸脱氢酶(G6PD)检测,随后根据G6PD状态和年龄等条件给予单剂他非诺喹300 mg、7天伯氨喹0.5 mg/kg每日或8周伯氨喹0.75 mg/kg每周。
  • 分析2021年9月9日至2022年8月31日记录的5554例间日疟患者,通过概率链接巴西疟疾流行病学监测系统的常规患者记录识别复发。
  • 使用Kaplan-Meier分析估计第90天和第180天无复发生效性,并通过多变量分析计算风险比(HR)。
  • 该临床试验注册号为ClinicalTrials.gov NCT05096702,已完成。

主要发现

  • 在所有任何年龄和任何G6PD状态的治疗患者中,第180天无复发生效性:他非诺喹组75.8%(95%CI 74.0-77.6),7天伯氨喹组73.4%(71.9-75.0),每周伯氨喹组82.1%(77.7-86.8)。
  • 在G6PD正常的16岁及以上患者中,第90天无复发生效性:他非诺喹组(n=2134)为88.6%(95%CI 87.2-89.9),7天伯氨喹组(n=370)为83.5%(79.8-87.4)。
  • 校正混杂因素后,他非诺喹相比7天伯氨喹的复发HR为0.65(95%CI 0.49-0.86;p=0.0031),第180天两种治疗结局相似(log-rank p=0.82)。
  • 在180天内,G6PD正常的16岁及以上患者中,他非诺喹组中位复发时间为92天(IQR 76-120),7天伯氨喹组为68天(52-94)。

关键数值与推荐

  • 他非诺喹300 mg单剂适用于G6PD正常、年龄≥16岁、未怀孕且未哺乳者。
  • 7天伯氨喹0.5 mg/kg每日适用于G6PD中间型或正常、年龄≥6个月、未怀孕且未哺乳或哺乳已超过1个月者。
  • 每周伯氨喹0.75 mg/kg共8周适用于G6PD缺乏、年龄≥6个月、未怀孕且未哺乳或哺乳已超过1个月者。

临床怎么用

  • 作者认为,包含G6PD定量检测和他非诺喹的间日疟根治治疗算法的公共卫生效益支持其在巴西及可能在整个南美洲实施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prevention of Plasmodium vivax malaria recurrence is essential for malaria elimination in Brazil. We evaluated the real-world effectiveness of an updated treatment algorithm for P vivax radical cure in the Brazilian Amazon. METHODS: In this non-interventional observational study, we used retrospective data from the implementation of a P vivax treatment algorithm at 43 health facilities in Manaus and Porto Velho, Brazil. The treatment algorithm consisted of chloroquine (25 mg/kg over 3 days) and point-of-care quantitative glucose-6-phosphate dehydrogenase (G6PD) testing followed by single-dose tafenoquine 300 mg (G6PD normal, aged ≥16 years, not pregnant and not breastfeeding), 7-day primaquine 0·5 mg/kg per day (G6PD intermediate or normal, aged ≥6 months, not pregnant, and not breastfeeding or breastfeeding for >1 month), or primaquine 0·75 mg/kg per week for 8 weeks (G6PD deficient, aged ≥6 months, not pregnant, and not breastfeeding or breastfeeding for >1 month). P vivax recurrences were identified from probabilistic linkage of routine patient records from the Brazilian malaria epidemiological surveillance system. Recurrence-free effectiveness at day 90 and day 180 was estimated using Kaplan-Meier analysis and hazard ratios (HRs) by multivariate analysis. This clinical trial is registered with ClinicalTrials.gov, NCT05096702, and is completed. FINDINGS: Records from Sept 9, 2021, to Aug 31, 2022, included 5554 patients with P vivax malaria. In all treated patients of any age and any G6PD status, recurrence-free effectiveness at day 180 was 75·8% (95% CI 74·0-77·6) with tafenoquine, 73·4% (71·9-75·0) with 7-day primaquine, and 82·1% (77·7-86·8) with weekly primaquine. In patients aged at least 16 years who were G6PD normal, recurrence-free effectiveness until day 90 was 88·6% (95% CI 87·2-89·9) in those who were treated with tafenoquine (n=2134) and 83·5% (79·8-87·4) in those treated with 7-day primaquine (n=370); after adjustment for confounding factors, the HR for recurrence following tafenoquine versus 7-day primaquine was 0·65 (95% CI 0·49-0·86; p=0·0031), with similar outcomes between the two treatments at day 180 (log-rank p=0·82). Over 180 days, median time to recurrence in patients aged at least 16 years who were G6PD normal was 92 days (IQR 76-120) in those treated with tafenoquine and 68 days (52-94) in those treated with 7-day primaquine. INTERPRETATION: In this real-world setting, single-dose tafenoquine was more effective at preventing P vivax recurrence in patients aged at least 16 years who were G6PD normal compared with 7-day primaquine at day 90, while overall efficacy at 180 days was similar. The public health benefits of the P vivax radical cure treatment algorithm incorporating G6PD quantitative testing and tafenoquine support its implementation in Brazil and potentially across South America. FUNDING: Brazilian Ministry of Health, Municipal and State Health Secretariats; Fiocruz; Medicines for Malaria Venture; Bill & Melinda Gates Foundation; Newcrest Mining; and the UK Government. TRANSLATION: For the Portuguese translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brito M, Rufatto R, Brito-Sousa JD, et al. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study. Lancet Infect Dis. 2024. PMID: 38452779. doi:10.1016/S1473-3099(24)00074-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。